Currently out of the existing stock ratings of Matt Hewitt, 92 are a BUY (82.88%), 18 are a HOLD (16.22%), 1 are a SELL (0.9%).

Matt Hewitt

Work Performance Price Targets & Ratings Chart

Analyst Matt Hewitt, currently employed at CRAIG HALLUM, carries an average stock price target met ratio of 49.42% that have a potential upside of 27.2% achieved within 175 days.

Matt Hewitt’s has documented 246 price targets and ratings displayed on 21 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on SLP, Simulations Plus at 13-Jun-2025.

Wall Street Analyst Matt Hewitt

Analyst best performing recommendations are on CDXS (CODEXIS).
The best stock recommendation documented was for SLP (SIMULATIONS PLUS) at 10/25/2021. The price target of $53 was fulfilled within 10 days with a profit of $12.07 (29.49%) receiving and performance score of 29.49.

Average potential price target upside

of $35.71 (44.04%) on LGND (LIGAND PHARMACEUTICALS).
of $65.26 (20.19%) on RGEN (REPLIGEN).
of $12.31 (26.89%) on SLP (SIMULATIONS PLUS).

CDMO Avid Bioservices CDXS Codexis LGND Ligand Pharmaceuticals OMCL Omnicell RGEN Repligen SDGR Schrodinger SRGA Surgalign Holdings TDOC Teladoc TLGT Teligent VCRA Vocera Communications AKRX Akorn APEN Apollo Endosurgery APYX Apyx Medical MDXG MiMedx Group CTEK CynergisTek SLP Simulations Plus TECH Bio-Techne Corp BLFS BioLife Solutions SNCE Science 37 Holdings ANGO AngioDynamics HSTM HealthStream

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Sean Dodge (RBC)